Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure - Results of the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program

Circulation

Volumn 113, Issue 7, 2006, Pages 986-994

  O'Meara, Eileen ^a,b   Clayton, Tim ^c   McEntegart, Margaret B ^a   McMurray, John J V ^a   Lang, Chim C ^d   Roger, Simon D ^e   Young, James B ^f   Solomon, Scott D ^g   Granger, Christopher B ^h   Östergren, Jan ⁱ   Olofsson, Bertil ^j   Michelson, Eric L ^k   Pocock, Stuart ^c   Yusuf, Salim ^l   Swedberg, Karl ^m   Pfeffer, Marc A ^f  

^a WESTERN INFIRMARY   (United Kingdom)

^b MONTREAL HEART INSTITUTE   (Canada)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e GOSFORD HOSPITAL   (Australia)

^f LERNER RESEARCH INSTITUTE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j ASTRAZENECA R AND D   (Sweden)

^k ASTRAZENECA   (United Kingdom)

^l HGH McMaster Clinic   (Canada)

^m SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Anemia; Heart failure; Hemoglobin; Kidney; Mortality

Indexed keywords

CANDESARTAN; BENZIMIDAZOLE DERIVATIVE; HEMOGLOBIN; TETRAZOLE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BODY MASS; CANADA; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ETHNOLOGY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; UNITED STATES; CONGESTIVE HEART FAILURE; HEART STROKE VOLUME; MIDDLE AGED; RACE; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANEMIA; BENZIMIDAZOLES; CONTINENTAL POPULATION GROUPS; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE, CONGESTIVE; HEMOGLOBINS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; RISK FACTORS; STROKE VOLUME; TETRAZOLES; TREATMENT OUTCOME;

EID: 33645094960     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.582577     Document Type: Article

References (37)

1. Maggioni AP, Opasich C, Anand I, Barlera S, Carbonierei E, Gonzini L, Tavazzi L, Latini R, Cohn J. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail. 2005;11:91-98.
2. Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J. 2005;149:391-401.
3. O'Meara E, Murphy C, McMurray JJV. Anaemia and heart failure: a review. Curr Heart Fail Rep. 2004;1:176-182.
4. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;38:955-962.
5. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780-1786.
6. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12065 patients with new-onset heart failure. Circulation. 2003;107:223-225.
7. Mozaffarian D, Nye R, Levy WC. Anaemia predicts mortality in severe heart failure: the Prospective Randomized Amlodipine Survival Evaluation. J Am Coll Cardiol. 2003;41:1933-1939.
8. Kosiborod M, Smith GL, Radford MJ, Foody JM, Krumholz HM. The prognostic importance of anemia in patients with heart failure. Am J Med. 2003;114:112-119.
9. Sharma R, Francis DP, Pitt B, Poole-Wilson PA, Coats AJ, Anker SD. Hb predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J. 2004;25:1021-1028.
10. Volpe M, Tritto C, Testa U, Rao MA, Martucci R, Mirante A, Enea I, Russo R, Rubattu S, Condorelli GL. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol. 1994;74:468-473.
11. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-1744.
12. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775-1780.
13. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294-299.
14. Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, Schwartz D, Baruch R, Yachnin T, Shaked M, Schwartz I, Steinbruch S, Iaina A. The effect of correction of anemia in diabetic and non diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 2003;18:141-146.
15. McMurray J, Östergren J, Pfeffer M, Swedberg K, Granger C, Yusuf S, Held P, Michelson E, Olofsson B, for the CHARM Committees and Investigators. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart Failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail. 2003;5:261-270.
16. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-766.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461-470.
18. McClellan WM, Flanders WD, Langsten RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol. 2002;13:1928-1936.
19. World Health Organisation. Nutritional anaemias: report of a WHO scientific group. WHO Tech Rep Ser. 1968;405:3-37.
20. Pocock SJ, Wang D, Pfeffer MA, McMurray JJV, Swedberg K, Ostergren J, Michelson EL, Pieper KS, Granger CB, for the CHARM Investigators. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27:65-75.
21. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104:2263-2268.
22. Locatelli F, Pisoni RL, Akizawa T, Cruz JM, DeOreo PB, Lameire NH, Held PJ. Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study findings. Am J Kidney Dis. 2004;44(suppl):27-33.
23. Thomas MC, Cooper ME, Tsalamandris C, MacIsaac R, Jerums G. Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med. 2005;165:466-469.
24. El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R, Bakris GL, Keane WF, Flack JM. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: the Kidney Early Evaluation Program. Kidney Int. 2005;67:1483-1488.
25. Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, Mancini DM. Hemodilution is common in patients with advanced heart failure. Circulation. 2003;107:226-229.
26. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, Yusuf S. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet. 2003;361:1077-1083.
27. Okonko DO, Anker SD. Anemia in chronic heart failure: pathogenetic mechanisms. J Card Fail. 10(1 Suppl):S5-9, 2004.
28. Katz SD. Mechanisms and treatment of anemia in chronic heart failure. Congest Heart Fail. 2004;10:243-247.
29. Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris PC. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J. 1993;70:357-362.
30. Anand IS, Chandrashekhar Y, Wander GS, Chawla LS. Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia. J Am Coll Cardiol. 1995;25:1402-1407.
31. Katz SD, Rao R, Berman JW, Schwarz M, Demopoulos L, Bijou R, LeJemtel TH. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation. 1994;90:12-16.
32. Anand I, McMurray JJ, Whitmore J, Warren M, Pham A, McCamish MA, Burton PB. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004;110:149-154.
33. Lauer MS, Evans JC, Levy D. Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). Am J Cardiol. 1992;70:1180-1184.
34. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-210.
35. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation. 2004;109:1004-1009.
36. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, Chiang YT, Aknay N, Maggioni AP, Opasich C, Latini R, Cohn JN. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation. 2005;112:1121-1127.
37. van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM, Schoemaker RG, Vellenga E, van Veldhuisen DJ, Voors AA, van Gilst WH. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysylproline partially explain the occurrence of anemia in heart failure. Circulation. 2005;112:1743-1747.